DEP regimen as a salvage therapy for refractory hemophagocytic lymphohistiocytosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-14005514

Enrollment

Unknown

Registered

2014-06-02

Start date

2014-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemophagocytic lymphohistiocytosis

Interventions

DEP:DEP regimen

Control:HLH-94 regimen

Eligibility

Sex/Gender

All

Age

1 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who did not achieve at least partial remission (PR) 2 weeks after initial standard HLH therapy; 2. Left ventricular ejection fraction higher than 50%; 3. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Heart function above grade II (NYHA); 2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2; 3. Pregnancy or lactating Women; 4. Allergic to Liposomal doxorubicin or etopside; 5. Active bleeding of the internal organs; 6. Participate in other clinical research at the same time.

Design outcomes

Primary

Measure	Time frame
sCD25;neutrophil;hemoglobin;thrombocyte;ferritin;triglyceride;glutamic-pyruvic transaminase;Hemophagocytosis;NK activity;sCD25;Fibrinogen;Total bilirubin;	—

Countries

China

Contacts

Public ContactWang Zhao

zhaowww263@outlook.com+86 13910623679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026